Soho Global Health Tbk PT
Soho Global Health Tbk PT is a pharmaceutical company that develops, produces, and distributes generic and branded medicines, primarily in Indonesia and Southeast Asia.
Business. Soho Global Health Tbk PT (SOHO.JK) is a pharmaceutical company engaged in the development and sale of healthcare products. The firm is headquartered in Indonesia and primarily listed on the Jakarta Stock Exchange (IDX). Specific details regarding its operating segments and geographic revenue mix are not disclosed.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Soho Global Health Tbk PT (SOHO.JK) is a pharmaceutical company engaged in the development and sale of healthcare products. The firm is headquartered in Indonesia and primarily listed on the Jakarta Stock Exchange (IDX). Specific details regarding its operating segments and geographic revenue mix are not disclosed.
Soho Global Health Tbk PT maintains a strong liquidity position, with a current ratio of 1.63, indicating the company can cover its short-term liabilities with its short-term assets. The company's free cash flow of 312.76 billion IDR and operating cash flow of 896.38 billion IDR support its liquidity profile, although its capital expenditures of -58.97 billion IDR suggest ongoing investment in operations.
In terms of profitability, the company's return on equity of 23.24% and return on assets of 9.75% are strong, outperforming the typical benchmarks for the pharmaceutical industry. These metrics suggest that Soho Global Health Tbk PT is effectively utilizing its equity and assets to generate returns, which is a positive sign for investors.
The company's revenue is primarily concentrated in Indonesia, with a significant portion of its operations and customer base located in the country. While the company has expanded into other Southeast Asian markets, its exposure to the Indonesian economy remains high, which could pose a concentration risk if the domestic market experiences economic downturns.
Looking ahead, Soho Global Health Tbk PT is expected to maintain a stable growth trajectory, with its revenue and profitability likely to remain resilient due to the consistent demand for pharmaceutical products. The company's strong cash flow generation and low debt levels provide a solid foundation for future growth and reinvestment.
The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The key risk flag is the negative net cash position after subtracting total debt, which could affect its ability to fund operations without external financing. However, the company's low debt-to-equity ratio of 0.0 suggests that it is not heavily leveraged, reducing the likelihood of financial distress.
Recent events, including the company's financial performance and strategic initiatives, have been disclosed in its latest financial filings. These documents highlight the company's focus on expanding its product portfolio and strengthening its market position in Indonesia and beyond.
- Soho Global Health Tbk PT has a strong liquidity position with a current ratio of 1.63.
- The company's return on equity of 23.24% and return on assets of 9.75% indicate effective use of equity and assets.
- Revenue is primarily concentrated in Indonesia, posing a potential concentration risk.
- The company is expected to maintain a stable growth trajectory with strong cash flow generation.
- The company has a low dilution risk and a medium liquidity risk.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Soho Global Health Tbk PT Market data — financials · 2026-05-29